Current Headlines

  1. Cerenis Receives EMA Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies
    9/3/2014

    Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, recently announced that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, specifically apoA-I deficiency and ABCA1 deficiency

  2. ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation For NUPLAZID (Pimavanserin) For Parkinson’s Disease Psychosis
    9/2/2014

    ACADIA Pharmaceuticals Inc. a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID (pimavanserin) for the treatment of Parkinson’s disease psychosis

  3. Boston Strategics Corporation Initiates A Phase 1 Clinical Trial Of The Anti-Cancer Agent ‘FF-10501’ For FUJIFILM In Patients With Advanced Hematologic Malignancies
    8/29/2014

    Boston Strategics Corporation (BSC), a primary global strategic drug development provider for FUJIFILM Pharmaceuticals U.S.A., Inc. (FPHU), has begun a Phase 1 clinical trial of FUJIFILM’s anti-cancer agent FF-10501 in the United States in patients with advanced hematologic malignancies, such as relapsed or refractory high-risk myelodysplastic syndromes (MDS)

  4. Simulations Plus Releases GastroPlus Version 8.6
    8/26/2014

    Simulations Plus, Inc. a leading provider of consulting services and software for pharmaceutical discovery and development, recently announced that it has released version 8.6 of its industry gold-standard GastroPlus simulation software

  5. AB SCIEX And Dalton Pharma Services Collaborate To Advance Antibody-Drug Conjugate Analysis
    8/26/2014

    AB SCIEX and Dalton Pharma Services (Dalton) recently announced a research collaboration to develop Antibody-Drug Conjugate (ADC) analysis capabilities. This will include development of more definitive and comprehensive method for the identification of drug loading and position of conjugation on macromolecules

  6. La Jolla Pharmaceutical Company Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome
    8/25/2014

    La Jolla Pharmaceutical Company a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, recently announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure

  7. Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer For Large & Small Molecule Analyses
    8/21/2014

    Aptuit LLC announces that Aptuit SSCI, located in West Lafayette, Indiana, has enhanced its capabilities in the areas of structure determination and characterization of small and large molecules, including biologic drugs, metabolites, and polymers, through the addition of the Bruker maXisPlus Q-TOF mass spectrometer

  8. Full Digitization Of The Anatomic Pathology Lab Is Here With The VENTANA System For Primary Diagnosis
    8/20/2014

    Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that its VENTANA System for Primary Diagnosis[1] has been CE marked in the European Union for routine pathology, including primary diagnosis with human tissue specimens

  9. ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application
    8/18/2014

    ARCA biopharma, Inc. a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, recently announced that the Company’s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada

  10. Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine
    8/14/2014

    Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds

Newsletter Signup
Get the latest industry news, insights, and analysis delivered to your inbox.
Join your peers